Your browser is no longer supported. Please, upgrade your browser.
Settings
VNRX VolitionRx Limited daily Stock Chart
VNRX [NYSE]
VolitionRx Limited
Index- P/E- EPS (ttm)-0.52 Insider Own9.20% Shs Outstand26.28M Perf Week-7.02%
Market Cap59.13M Forward P/E- EPS next Y-0.58 Insider Trans- Shs Float19.25M Perf Month-16.04%
Income-13.30M PEG- EPS next Q-0.15 Inst Own22.00% Short Float0.77% Perf Quarter-29.91%
Sales- P/S- EPS this Y3.90% Inst Trans-2.82% Short Ratio3.89 Perf Half Y-40.48%
Book/sh0.63 P/B3.57 EPS next Y-5.50% ROA-64.40% Target Price7.67 Perf Year-54.73%
Cash/sh0.63 P/C3.58 EPS next 5Y- ROE-78.00% 52W Range2.28 - 5.45 Perf YTD-50.77%
Dividend- P/FCF- EPS past 5Y-2.70% ROI- 52W High-58.72% Beta-1.59
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low-1.32% ATR0.13
Employees18 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)36.02 Volatility3.84% 5.01%
OptionableNo Debt/Eq0.14 EPS Q/Q-4.20% Profit Margin- Rel Volume0.44 Prev Close2.33
ShortableYes LT Debt/Eq0.13 EarningsNov 08 BMO Payout- Avg Volume38.20K Price2.25
Recom2.00 SMA20-13.81% SMA50-15.74% SMA200-36.79% Volume16,841 Change-3.43%
Sep-07-16Reiterated Rodman & Renshaw Buy $12 → $10
Feb-01-16Initiated Rodman & Renshaw Buy $12
Sep-22-17 08:30AM  VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits PR Newswire +11.19%
Sep-21-17 04:30PM  VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding PR Newswire
Sep-19-17 04:30PM  VolitionRx Announces its European Colorectal Cancer Strategy PR Newswire
Sep-15-17 07:30AM  VolitionRx to Attend Two Major Conferences in Asia PR Newswire
Sep-14-17 08:00AM  Volition Granted Four Additional Patents PR Newswire
Sep-07-17 04:30PM  GVC Capital and Trickle Research Announce Preliminary Presenter Schedule for Inaugural Rocky Mountain MicroCap Conference in Denver on September 25, 2017 Marketwired
Sep-06-17 04:30PM  VolitionRx Limited to Attend Multiple Conferences in September PR Newswire
Aug-30-17 07:00AM  VNRX: Pathway Design Study Progressing. Expect European Launch in 2018 Zacks Small Cap Research +10.61%
Aug-22-17 04:30PM  Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers PR Newswire
Aug-10-17 07:41PM  VolitionRX reports 2Q loss Associated Press
Aug-09-17 04:05PM  VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update PR Newswire
Aug-03-17 04:30PM  VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update PR Newswire -5.20%
Aug-01-17 09:00AM  VNRX: Large U.S. Study Comes Cheap, Could Support Asymptomatic FDA Filing Zacks Small Cap Research +7.97%
Jul-19-17 04:30PM  VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute PR Newswire
Jul-18-17 06:30AM  Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute PR Newswire
Jun-30-17 09:22AM  Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress PR Newswire
Jun-29-17 01:00PM  VNRX: Replacing Triage Assays Could Be Non-Event Zacks Small Cap Research
Jun-27-17 07:30AM  VolitionRx Limited Corrects an Earlier Announcement PR Newswire -9.74%
May-26-17 06:30AM  VolitionRx Limited to Present at Multiple Investor Conferences in June PR Newswire
May-23-17 12:10PM  VNRX: Closing In On EU Launch, Asia Could Be Next Zacks Small Cap Research +13.61%
May-18-17 09:00AM  A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays PR Newswire
May-11-17 06:36AM  VolitionRX reports 1Q loss Associated Press +7.26%
06:30AM  VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update PR Newswire
May-09-17 07:30AM  VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test PR Newswire
May-08-17 08:00AM  VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update PR Newswire
Apr-27-17 07:46AM  Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe PR Newswire
Apr-21-17 08:26AM  Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory PR Newswire
Apr-11-17 07:00AM  VolitionRx Appoints David Vanston as Chief Financial Officer PR Newswire
Mar-28-17 04:01PM  Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States PR Newswire
Mar-21-17 11:00AM  VNRX: Logistics Validation And Danish Launch Could Be Upcoming Zacks Small Cap Research -5.50%
Mar-20-17 06:30AM  VolitionRx Limited Announces the Formation of Volition America, Inc. PR Newswire
Mar-16-17 04:03PM  VOLITIONRX LTD Files SEC form 8-K, Results of Operations and Financial Condition
Mar-15-17 01:04PM  VOLITIONRX LTD Financials
Mar-14-17 01:56PM  VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange PR Newswire
Mar-13-17 06:30AM  VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time PR Newswire
Mar-10-17 07:13AM  VOLITIONRX LTD Files SEC form 10-K, Annual Report
07:07AM  Q4 2016 VolitionRX Ltd Earnings Release - Before Market Open
06:58AM  VolitionRX reports 4Q loss Associated Press
06:30AM  VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update PR Newswire
Mar-08-17 06:30AM  VolitionRx Limited to Present at the 29th Annual ROTH Conference PR Newswire +6.25%
Mar-06-17 05:00PM  VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update PR Newswire
Mar-02-17 06:30AM  A Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark PR Newswire
Feb-24-17 06:30AM  VolitionRx Limited's Triage Test Results Validated in Prospective Trial PR Newswire
Feb-23-17 09:00AM  VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference PR Newswire
Feb-09-17 09:26AM  VolitionRx Limited to Present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference on February 15, 2017 PR Newswire
Jan-07-17 04:44PM  2 Medical Companies at Forefront of Oncology Testing
Jan-05-17 06:30AM  VolitionRx Limited Strengthens Team with Key Appointment to Drive Sales and Trials in Asia PR Newswire +5.84%
Jan-04-17 12:00PM  VNRX: Triage CE Marked. More Details Next Week at JPM Conference
Jan-03-17 09:00AM  VolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe PR Newswire
Dec-28-16 06:30AM  VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference PR Newswire
Dec-01-16 08:57AM  VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference PR Newswire
08:41AM  VolitionRX Ltd. :VNRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-18-16 11:20AM  VNRX: More Details on Triage Strategy, Launch Still Expected in 2017 +9.27%
Nov-15-16 05:10PM  VOLITIONRX LTD Files SEC form 8-K, Results of Operations and Financial Condition
Nov-11-16 06:30AM  VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016 PR Newswire
Nov-10-16 06:36AM  VolitionRX reports 3Q loss
06:30AM  VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update PR Newswire
06:02AM  VOLITIONRX LTD Files SEC form 10-Q, Quarterly Report
Nov-04-16 06:30AM  VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update PR Newswire +8.42%
Nov-03-16 06:30AM  VolitionRx Limited and Hvidovre Hospital Begin Large Prospective Clinical Study PR Newswire
Oct-26-16 06:30AM  VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition PR Newswire
Oct-21-16 11:34AM  VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter PR Newswire
Oct-13-16 09:00AM  SeeThruEquity Issues Update on VolitionRX (VNRX) and Raises Price Target to $7.00 Accesswire -7.40%
Oct-11-16 04:39PM  VOLITIONRX LTD Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Mat
11:59AM  VolitionRX Ltd. to Present at The MicroCap Conference on October 24-25 in Philadelphia Accesswire
08:30AM  Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25% PR Newswire
Oct-05-16 12:14PM  VolitionRx Limited Announces Closing of Public Offering of Common Stock PR Newswire
Sep-30-16 08:45AM  VolitionRx Limited Announces Pricing of Public Offering of Common Stock PR Newswire
Sep-29-16 04:02PM  VolitionRx Limited Announces Proposed Public Offering of Common Stock PR Newswire
Sep-07-16 02:00PM  VNRX: Initial Product Will Be Complement To Current CRC Screens +9.07%
06:30AM  VolitionRx to Attend Several Conferences in September PR Newswire
Sep-06-16 06:30AM  Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent PR Newswire +8.83%
Sep-01-16 06:30AM  VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET PR Newswire
Aug-16-16 04:32PM  VOLITIONRX LTD Files SEC form 8-K, Results of Operations and Financial Condition
Aug-15-16 12:30PM  VNRX: E.U. Launch Expected Early 2017. More Details in Sept / Oct
Aug-11-16 06:39AM  VolitionRX reports 2Q loss
06:30AM  VolitionRx Announces Second Quarter 2016 Financial Results and Business Update PR Newswire
06:03AM  VOLITIONRX LTD Files SEC form 10-Q, Quarterly Report
Aug-08-16 06:30AM  VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET PR Newswire
Aug-02-16 07:00AM  VolitionRx Engages Edison Advisors as Investor Relations Counsel PR Newswire +5.54%
Jul-27-16 07:00AM  VolitionRx Granted Fourth U.S. Patent PR Newswire
Jun-24-16 07:00AM  VolitionRx Appoints Dr. Edward Futcher to Board of Directors PR Newswire
Jun-14-16 07:00AM  VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests PR Newswire
Jun-08-16 06:09PM  VolitionRX Ltd. :VNRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
May-31-16 09:15AM  VolitionRx to Present at Two Upcoming Conferences in June PR Newswire +9.67%
May-23-16 09:00AM  SeeThruEquity Issues Update Note on VolitionRx (NYSE MKT: VNRX) with a Price Target of $6.70 Accesswire
May-19-16 05:09PM  VOLITIONRX LTD Files SEC form 8-K, Results of Operations and Financial Condition
12:45PM  VNRX: EU Launch Upcoming. New, Large Pancreatic Cancer Study Initiated
07:00AM  VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting PR Newswire
May-13-16 07:19AM  VolitionRX reports 1Q loss
07:00AM  VolitionRx Announces First Quarter 2016 Financial Results and Business Update PR Newswire
06:03AM  VOLITIONRX LTD Files SEC form 10-Q, Quarterly Report
May-12-16 07:00AM  VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer PR Newswire
May-09-16 07:00AM  VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET PR Newswire
Apr-20-16 09:00AM  VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test PR Newswire
Apr-14-16 07:00AM  VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer PR Newswire
Apr-11-16 07:00AM  VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series PR Newswire
Apr-08-16 07:00AM  VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study PR Newswire
Apr-07-16 07:08AM  VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer PR Newswire
Mar-23-16 11:30AM  VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full PR Newswire +6.28%
VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants. The company also develops blood assays in the Nu.Q-M family to detect nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; blood assays in the Nu.Q-A family to detect nucleosome-protein adducts; and a Nu.Q-T assay to detect cancer by detecting total blood nucleosome levels. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.